Navigation Links
Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
Date:6/26/2012

FARMINGTON, Conn., June 26, 2012 /PRNewswire-iReach/ -- As the global economy recovers from recession, the drug discovery industry – which weathered the downturn better than most – are poised for a significant period of new growth. To make the most of this surge in business and make better business decisions, companies need the best, most accurate market data available. Global Information, Inc. is pleased to announce a slate of new drug discovery market forecasts and pipeline assessments from partner publishing firm GlobalData.

(Photo:  http://photos.prnewswire.com/prnh/20120626/CG31054)

Acute Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The pain management market is ripe with immediate opportunities particularly for reformulations and the generics segment. The looming patent cliff means that generic competition will become increasingly relevant as the current market leaders go off patents. This report provides analyses of key recent licensing and partnership agreements in the acute pain therapeutics market. Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications. Product profiles are included for the following major marketed products in the acute pain therapeutics market: Celebrex, DepoDur, Ofirmev, Oxecta, Nucynta, Dilaudid, Sprix, Zipsor, Flector Patch and Vicoprofen.

Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Tentative approval from the FDA for generic version of Cymbalta (duloxetine) is on the horizon. The generic market for Cymbalta will be hotly contested despite a U.S. District Court- issued order prohibiting sale of generic duloxetine prior to patent expiry in June 2013. What's the next big thing in the global Osteoarthritis Pain Therapeutics market landscape? - Identify, understand and capitalize by reading this new report.

Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Bayer recently announced trials of blockbuster Regorafenib have showed promise against gastrointestinal cancer. The German drugmaker added that it will seek approval for wider use of Regorafenib. This report includes molecule profiles for Regorafenib (BAY 73-4506) as well as other late-stage molecules under clinical development including Mastinib, Nexavar (sorafenib) and Tasigna (nilotinib). Clinical trial mapping for gastrointestinal stromal tumors therapeutics is also provided by country, by phase, by trial status, by prominent sponsors and by companies.

Infectious Immunology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

Rising demand for hepatitis and HIV testing is set to increase the value of the infectious immunology market. The global infectious immunology market is projected to grow at a CAGR of 7.3% through 2018. The US currently ranks as the largest market for infectious immunology testing with nearly 36% of global revenue. Large testing volumes, high public awareness and reimbursement availability are significant factors contributing to the US infectious immunology testing market. Infectious immunology markets of emerging nations are small relative to developed countries, but they have witnessed the highest growth rates in the past decade. China's infectious immunology market is expected reach revenues close to a billion dollars while the market in India is forecast to reach revenues of nearly $200 million by 2018.

Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

Millions of Americans have hepatitis, but most don't know it. The market for preventative vaccines like Havrix, Vaqta, Twinrix, Ambirix, Avaxim and Epaxal from GlaxoSmithKline, Merck & Co, and Crucell are working to reduce the number of hepatitis contractions worldwide. This report provides information on the key drivers and challenges of the Hepatitis A Preventive Vaccines market.

Traumatic Brain Injury Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The traumatic brain injury therapeutics market was valued at $1.25 billion in 2011 and is expected to rise at a compound annual growth rate of 2.8% reaching $1.55 billion by 2019. Traumatic brain injury (TBI) is a major cause of death and disability. An estimated 5.3 million people are living with a permanent TBI-related disability in the U.S. while a third of all injury related deaths are attributed to traumatic brain injury.

Post Traumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019

An essential source of information and analysis that identifies key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report provides valuable insights on pipeline products, the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.

Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The gout space is heating up, but is there sufficient room in the market to accommodate multiple new therapeutics? Major marketed classes of products for treatment of gout include NSAIDs, corticosteroids, Colcrys (Colchicines), Allopurinol, Probenecid, Uloric, Adenuric (febuxostat) and Krystexxa (Pegloticase). In recent news, new analysis of phase III trials showed gout patients with chronic kidney disease responding to Krystexxa. Earlier this month Takeda Pharmaceuticals announced the completion of its acquisition of URL Pharma which will add Colcrys (colchicine) to Takeda's gout treatment portfolio moving forward.

Methicillin-resistant Staphylococcus aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

The number of methicillin-resistant staphylococcus aureus (MSRA) infection cases appears to be declining nationwide according to the most recent data release by the U.S. Department of Health and Human Services. In 2005, for every 100,000 people nearly 36 individuals contracted MSRA infections. That number has declined to 21 in 2010. The U.S. government aims to keep infection rates down to 13 per 100,000 people by 2013. This report provides profiles of the most promising drugs used to treat MSRA infections such as Torezolid phosphate (TR-701, Tedizolid), Ceftobiprole Medocaril, Dalbavancin and Oritavancin.

Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market in future. Develop business strategies by understanding the trends shaping and driving the global Acute Respiratory Distress Syndrome (ARDS) Therapeutics market.

About Global Information, Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world.

Media Contact: Jeremy Palaia, Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
2. ConvaTec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Attendees Save Up To $800 on Global Healthcare Conferences in 2012 by Registering Through Global Information Inc.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced it has earned a spot ... 2017" list. The Company was ranked among 500 U.S. ... Employers and Healthcare Equipment and Services. The ... on an anonymous, independent survey of over 30,000 employees ...
(Date:5/9/2017)... 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug ... Property Office has granted Oramed a patent titled, ... The patent covers Oramed,s invention of an oral ... an incretin hormone that stimulates the secretion of ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as ... production of the series is on hiking in American. Viewers can reconnect with America ... great benefits of hiking. , Many consumers have looked for an inventive new place ...
(Date:5/26/2017)... ... ... FAMILY-Our Journey to the Cross”: the personal journey of Bob Massey and his faith in ... authors, Bob and Margaret Massey. Bob Massey is small in stature but big in ... His love for others is apparent in all of his life decisions. , ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the ... is the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist ... Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... ... May 24, 2017 , ... In ... choosing the most appropriate instruments for research and understanding the basic principles that ... webinar will focus on innovations in stereo microscopy for brightfield and fluorescence typically ...
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ™, ... has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ... secure cloud platform for medical image management. At the core is patented streaming ...
Breaking Medicine News(10 mins):